tucidinostat + azacitidine + cyclophosphamide + doxorubicin + vincristine + prednisone

This is a multi-agent combination regimen consisting of six drugs: - **Tucidinostat** (also known as chidamide, Epidaza, Hiyasta): an oral, subtype-selective histone deacetylase (HDAC) inhibitor that targets HDAC1, HDAC2, HDAC3, and HDAC10. It is approved for relapsed/refractory peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia/lymphoma in China and Japan. Tucidinostat has demonstrated synergistic effects with chemotherapy and immunotherapy in hematological malignancies[1][2][5]. - **Azacitidine**: a DNA methyltransferase inhibitor used primarily in myelodysplastic syndromes and acute myeloid leukemia; it induces hypomethylation of DNA leading to reactivation of tumor suppressor genes. - **Cyclophosphamide**: an alkylating agent that crosslinks DNA strands to inhibit cell division; widely used in lymphomas as part of CHOP or R-CHOP regimens[8][9]. - **Doxorubicin**: an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II activity; commonly used for various cancers including lymphomas[8][9]. - **Vincristine**: a vinca alkaloid that inhibits microtubule formation during mitosis; standard component of lymphoma regimens such as CHOP/R-CHOP[8][9]. - **Prednisone**: a synthetic glucocorticoid corticosteroid with anti-inflammatory and cytotoxic properties against certain cancer cells[8][9]. This combination represents an investigational regimen designed to leverage the epigenetic modulation by tucidinostat alongside the cytotoxic effects of conventional chemotherapeutic agents plus steroid therapy. The rationale is based on evidence showing improved outcomes when combining tucidinostat with CHOP-like regimens in newly diagnosed PTCL patients compared to chemotherapy alone[5]. Azacitidine adds further epigenetic modulation.

Other names

tucidinostat + azacitidine + cyclophosphamide + doxorubicin + vincristine + prednisone